Skip to main content
Log in

Immunotoxicology of beryllium lung disease

  • Minireview Article
  • Published:
Environmental Health and Preventive Medicine Aims and scope

Abstract

Beryllium induces non-caseating granulomatous inflammation in humans exposed to the metal dust or fumes in both occupational and non-occupational settings. The resulting condition, chronic beryllium disease (CBD), affects principally the lungs, lymphatics, and skin and continues to plague modern industry. Beryllium exerts several important immunotoxic effects, including induction of a beryllium-antigen specific adaptive immune response and the triggering of inflammatory and innate immune responses. Genetic susceptibility plays a role in CBD adaptive immune responses, mainly mediated through single nucleotide polymorphisms in HLA-DP and, to a lesser extent, HLA-DR. The adaptive response is characterized by influx and proliferation of CD4+ central and effector memory T cells expressing Th1 cytokines. Insights into the immunopathogenesis of CBD have implications for the understanding of other immune-mediated granulomatous disorders and for metal antigen behavior.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Infante P, Newman LS. Beryllium exposure and chronic beryllium disease. Lancet 2004;363:415–416.

    Article  PubMed  Google Scholar 

  2. Maier LA, Gunn C, Newman LS. Beryllium Disease. In: Rom WN and Markowitz SB editors. Environmental and Occupational Medicine, 4th ed, Philadelphia: Woltersw Kluwer/Lippincott Williams and Wilkins; 2007. pp. 1019–1038.

    Google Scholar 

  3. Sterner JH, Eisenbud M. Epidemiology of beryllium intoxication. Arch Industr Hyg Occup Med. 1951;4:123–151.

    CAS  Google Scholar 

  4. Curtis GH. Cutaneous hypersensitivity due to beryllium: a study of thirteen cases. AMA Arch Dermatol Syph. 1951;64: 470–482.

    CAS  Google Scholar 

  5. Hanifin JM, Epstein WL, Cline MJ. In vitro studies of granulomatous hypersensitivity to beryllium. J Invest Dermatol. 1970;55:284–288.

    Article  PubMed  CAS  Google Scholar 

  6. Mroz MM, Kreiss K, Lezotte DC, Campbell PA, Newman LS. Reexamination of the blood lymphocyte transformation test in the diagnosis of chronic beryllium disease. J Allergy Clin Immunol. 1991;88:54–60.

    Article  PubMed  CAS  Google Scholar 

  7. Stange AW, Furman FJ, Hilmas DE. The beryllium lymphocyte proliferation test: relevant issues in beryllium health surveillance. Am J Ind Med. 2004;46:453–462.

    Article  PubMed  Google Scholar 

  8. Fontenot AP, Maier LA. Genetic susceptibility and immune-mediated destruction in beryllium-induced disease. Trends Immunol. 2005;26:543–549.

    Article  PubMed  CAS  Google Scholar 

  9. Inoue Y, Barker E, Daniloff E, Kohno N, Hiwada K, Newman LS. Pulmonary epithelial cell injury and alveolar-capillary permeability in berylliosis. Am J Respir Crit Care Med. 1997;156:109–115.

    PubMed  CAS  Google Scholar 

  10. Sawyer RT, Doherty DA, Schumacher BA, Newman LS. Beryllium-stimulatedin vitro migration of peripheral blood lymphocytes. Toxicology. 1999;138:155–163.

    Article  PubMed  CAS  Google Scholar 

  11. Bost TW, Riches DW, Schumacher B, Carré PC, Khan TZ, Martinez JA, et al. Alveolar macrophages from patients with beryllium disease and sarcoidosis express increased levels of mRNA for tumor necrosis factor-alpha and IL-6 but not IL-1β. Am J Respir Cell Mol Biol. 1994;10:506–513.

    PubMed  CAS  Google Scholar 

  12. Saltini C, Winestock K, Kirby M, Pinkston P, Crystal RG. Maintenance of alveolitis in patients with chronic beryllium disease by beryllium-specific helper T cells. N Engl J Med. 1989;320:1103–1109.

    PubMed  CAS  Google Scholar 

  13. Saltini C, Kirby M, Trapnell BC,Tamura N, Crystal RG. Biased accumulation of T lymphocytes with “memory”-type CD45 leukocyte common antigen gene expression on the epithelial surface of the human lung. J Exp Med. 1990;171:1123–1140.

    Article  PubMed  CAS  Google Scholar 

  14. Tinkle SS, Kittle LA, Schumacher BA, Newman LS. Beryllium induces IL-2 and IFN-gamma in berylliosis J Immunol. 1997;158:518–526.

    PubMed  CAS  Google Scholar 

  15. Tinkle SS, Kittle LA, Newman LS. Partial IL-10 inhibition of cell-mediated immune response in chronic beryllium disease. J Immunol. 1999;163:2747–2753.

    PubMed  CAS  Google Scholar 

  16. Fontenot AP, Canavera SJ, Gharavi L, Newman LS, Kotzin BL. Target organ localization of CD4+T cells in patients with chronic beryllium disease. J Clin Invest. 2002;110:1473–1482.

    PubMed  CAS  Google Scholar 

  17. Fontenot A, Kotzin B, Comment CE, Newman LS. Expansions of T cell subsets expressing particular T cell receptor variable regions in chronic beryllium disease Am J Respir Cell Mol Biol. 1998;18:581–589.

    PubMed  CAS  Google Scholar 

  18. Fontenot AP, Falta MT, Freed BM, Newman LS, Kotzin BL. Identification of pathogenic T cells in patients with beryllium-induced lung disease. J Immunol 1999;163:1019–1026.

    PubMed  CAS  Google Scholar 

  19. Fontenot AP, Palmer BE Sullivan AK, Joslin FG, Wilson CC, Maier LA, et al. Frequency of beryllium-specific, central memory CD4+T cells in blood determines proliferative response. J Clin Invest. 2005;115:2886–2893.

    Article  PubMed  CAS  Google Scholar 

  20. Fontenot AP Gharavi L, Bennett SR, Canavera SJ, Newman LS, Kotzin BL. CD28 costimulation independence of target organ versus circulating memory antigen-specific CD4+T cells. J Clin Invest. 2003;112:776–784.

    PubMed  CAS  Google Scholar 

  21. Bobka CA, Stewart LA, Engelken GJ, Golitz LE, Newman LS. Comparison ofin vivo andin vitro measures of beryllium sensitization. J Occup Environ Med. 1997;39:540–547.

    Article  PubMed  CAS  Google Scholar 

  22. Fontenot AP, Maier LA, Canavera SJ, Hendry-Hofer TB, Boguniewicz M Barker EA, et al. Beryllium skin patch testing to analyze T cell stimulation and granulomatous inflammation in the lung. J Immunol. 2002;168:3627–3634.

    PubMed  CAS  Google Scholar 

  23. Amicosante M, Berretta F, Franchi A, Rogliani P, Dotti C, Losi M, et al. HLA-DP-unrestricted TNF-alpha release in beryllium-stimulated peripheral blood mononuclear cells. Eur Respir J. 2002;20:1174–1178.

    Article  PubMed  CAS  Google Scholar 

  24. Sawyer RT, Day BJ, Fadok VA, Chiarappa-Zucca M, Maier LA, Fontenot AP, et al. Beryllium-ferritin: lymphocyte proliferation and macrophage apoptosis in chronic beryllium disease. Am J Respir Cell Mol Biol. 2004;31:470–477.

    Article  PubMed  CAS  Google Scholar 

  25. Richeldi L, Sorrentino R, Saltini C. HLA-DPBI glutamate 69:a genetic marker of beryllium disease. Science. 1993;262:242–244.

    Article  PubMed  CAS  Google Scholar 

  26. Newman LS. To Be2+ or not to Be2+: immunogenetics and occupational exposure. Science. 1993;262:197–198.

    Article  PubMed  CAS  Google Scholar 

  27. Fontenot AP Torres M, Marshall WH, Newman LS, Kotzin BL. Beryllium presentation to CD4+T cells underlies disease-susceptibility HLA-DP alleles in chronic beryllium disease. Proc Natl Acad Sci USA 2000;97:12717–12722.

    Article  PubMed  CAS  Google Scholar 

  28. Fontenot AP, Newman LS, Kotzin BL. Chronic beryllium disease: T cell recognition of a metal presented by HLA-DP. Clin Immunol. 2001;100:4–14.

    Article  PubMed  CAS  Google Scholar 

  29. Wang Z, White PS, Petrovic M, Tatum OL Newman LS, Maier LA, et al. Differential susceptibilities to chronic beryllium disease contributed by different Glu69 HLA-DPB1 and-DPA1 alleles. J Immunol. 1999;163:1647–1653.

    PubMed  CAS  Google Scholar 

  30. Maier LA, Sawyer RT, Bauer RA, Kittle LA, Lympany P, McGrath D, et al. High beryllium-stimulated TNF-alpha is associated with the-308 TNF-alpha promoter polymorphism and with clinical severity in chronic beryllium disease. Am J Respir Crit Care Med. 2001;164:1192–1199.

    PubMed  CAS  Google Scholar 

  31. Wang Z, Farris GM, Newman LS, Shou Y, Maier LA, Smith HN, et al. Beryllium sensitivity is linked to HLA-DP genotype. Toxicology. 2001;165:27–38.

    Article  PubMed  CAS  Google Scholar 

  32. Saltini C, Richeldi L, Losi M, Amicosante M, Voorter C, van den Berg-Loonen E, et al. Major histocompatibility locus genetic markers of beryllium sensitization and disease. Eur Respir J. 2001;18:677–684.

    Article  PubMed  CAS  Google Scholar 

  33. Rossman MD, Stubbs J, Lee CW, Argyris E, Magira E, Monos D. Human leukocyte antigen Class II amino acid epitopes: susceptibility and progression markers for beryllium hypersensitivity. Am J Respir Crit Care Med. 2002;165:788–794.

    PubMed  Google Scholar 

  34. Lombardi G, Germain C, Uren J, Fiorillo MT, du Bois RM, Jones-Williams W, et al. HLA-DP allele-specific T cell responses to beryllium account for DP-associated susceptibility to chronic beryllium disease. J Immunol. 2001;166:3549–3555.

    PubMed  CAS  Google Scholar 

  35. Weston A, Snyder J, McCanlies EC, Schuler CR, Andrew ME, Kreiss K, et al. Immunogenetic factors in beryllium sensitization and chronic beryllium disease. Mutat Res. 2005; 592:68–78.

    PubMed  CAS  Google Scholar 

  36. McCanlies EC, Kreiss K, Andrew M, Weston A. HLA-DPB1 and chronic beryllium disease: a HuGE review. Am J Epidemiol. 2003;157:388–398.

    Article  PubMed  Google Scholar 

  37. Maier LA, McGrath DS, Sato H, Lympany P, Welsh K, Du Bois R, et al. Influence of MHC class II in susceptibility to beryllium sensitization and chronic beryllium disease. J Immunol. 2003;171:6910–6918.

    PubMed  CAS  Google Scholar 

  38. Amicosante M, Fontenot AP. T cell recognition in chronic beryllium disease. Clin Immunol. 2006;121:134–143.

    Article  PubMed  CAS  Google Scholar 

  39. Amicosante M, Berretta F, Rossman M, Butler RH, Rogliani P, van den Berg-Loonen E, et al. Identification of HLA-DRPhebeta47 as the susceptibility marker of hypersensitivity to beryllium in individuals lacking the berylliosis-associated supratypic marker HLA-DPGlubeta69. Respir Res. 2005;6:94.

    Article  PubMed  CAS  Google Scholar 

  40. Bill JR, Mack DG, Falta MT, Maier LA, Sullivan AK, Joslin FG, et al. Beryllium presentation to CD4+T cells is dependent on a single amino acid residue to the MHC class II betachain. J Immunol. 2005;175:7029–7037.

    PubMed  CAS  Google Scholar 

  41. Richeldi L, Kreiss K, Mroz MM, Zhen B, Tartoni P, Saltini C. Interaction of genetic and exposure factors in the prevalence of berylliosis. Am J Ind Med. 1997;32:337–340.

    Article  PubMed  CAS  Google Scholar 

  42. Kittle LA, Sawyer RT, Fadok VA, Maier LA, Newman LS. Beryllium induces apoptosis in human lung macrophages. Sarcoidosis Vasc Diffuse Lung dis. 2002;19:101–113.

    PubMed  Google Scholar 

  43. Sawyer RT, Parsons CE, Fontenot AP, Maier LA, Gillespie MM, Gottschall EB, et al. Beryllium-induced TNF-alpha production by CD4+T cells is mediated by HLA-DP. Am J Respir Cell Mol Biol. 2004;31:122–130.

    Article  PubMed  CAS  Google Scholar 

  44. Sawyer RT, Dobis DR, Goldstein M, Velsor L, Maier LA, Fontenot AP, et al. Beryllium-stimulated reactive oxygen species and macrophage apoptosis. Free Radic Biol Med. 2005;38:928–937.

    Article  PubMed  CAS  Google Scholar 

  45. Sawyer RT, Fontenot AP Barnes TA, Parsons CE, Tooker BC, Maier LA, et al. Beryllium-induced TNF-alpha production is transcription-dependent in chronic beryllium disease. Am J Respir Cell Mol Biol. 2007;36:191–200.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Lee S. Newman.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Newman, L.S. Immunotoxicology of beryllium lung disease. Environ Health Prev Med 12, 161–164 (2007). https://doi.org/10.1007/BF02897985

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02897985

Key words

Navigation